Effects of a Paleolithic diet compared to a diabetes diet on leptin binding inhibition in secondary analysis of a randomised cross-over study.


Journal

BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676

Informations de publication

Date de publication:
04 Sep 2024
Historique:
received: 05 04 2024
accepted: 30 08 2024
medline: 5 9 2024
pubmed: 5 9 2024
entrez: 4 9 2024
Statut: epublish

Résumé

Beneficial effects from practising a Paleolithic diet as compared to a diabetes diet on weight, waist circumference, satiety, leptin, HbA1c and glucose control in randomised controlled trial participants with type 2 diabetes could be due to lower leptin resistance. Support for this hypothesis comes from an in vitro experiment that showed that digested wheat gluten, which is excluded from a Paleolithic diet, inhibits leptin from binding to its receptor, thus indicating a possible dietary cause of leptin resistance. However, the clinical relevance of the latter finding is unclear since removal of enzyme activity from the gluten digest by heat treatment also abolished leptin binding inhibition. Assessment of leptin binding inhibition in vivo is possible by comparison of total leptin levels with those of 'biologically active' leptin bound to its receptor (bioLep). To assess the effects of a Paleolithic diet compared to a diabetes diet on leptin binding inhibition and to replicate our in vitro study. BioLep and total leptin levels were measured in secondary analysis of fasting plasma samples from our open label random order three plus three-month long cross-over trial performed in 2005-2007, that compared a Paleolithic diet with a diabetes diet in participants with type 2 diabetes without insulin treatment (per protocol). BioLep was also measured in vitro for known recombinant leptin concentrations incubated with a series of concentrations of 10 kDa spin-filtered digested wheat gluten, with or without prior heat treatment, at 100ºC for 30 min and centrifugation. There was no difference between diets when comparing differences between bioLep and total leptin levels and their ratio in the 13 participants, three women and 10 men, aged 52-74 years with a mean BMI of 30 kg/m We found no leptin binding inhibition after the Paleolithic or diabetes diet, possibly due to its abolishment from cooking-related heat treatment of wheat gluten. Registered on 14/02/2007 at ClinicalTrials.gov Identifier: NCT00435240.

Sections du résumé

BACKGROUND BACKGROUND
Beneficial effects from practising a Paleolithic diet as compared to a diabetes diet on weight, waist circumference, satiety, leptin, HbA1c and glucose control in randomised controlled trial participants with type 2 diabetes could be due to lower leptin resistance. Support for this hypothesis comes from an in vitro experiment that showed that digested wheat gluten, which is excluded from a Paleolithic diet, inhibits leptin from binding to its receptor, thus indicating a possible dietary cause of leptin resistance. However, the clinical relevance of the latter finding is unclear since removal of enzyme activity from the gluten digest by heat treatment also abolished leptin binding inhibition. Assessment of leptin binding inhibition in vivo is possible by comparison of total leptin levels with those of 'biologically active' leptin bound to its receptor (bioLep).
OBJECTIVES OBJECTIVE
To assess the effects of a Paleolithic diet compared to a diabetes diet on leptin binding inhibition and to replicate our in vitro study.
METHODS METHODS
BioLep and total leptin levels were measured in secondary analysis of fasting plasma samples from our open label random order three plus three-month long cross-over trial performed in 2005-2007, that compared a Paleolithic diet with a diabetes diet in participants with type 2 diabetes without insulin treatment (per protocol). BioLep was also measured in vitro for known recombinant leptin concentrations incubated with a series of concentrations of 10 kDa spin-filtered digested wheat gluten, with or without prior heat treatment, at 100ºC for 30 min and centrifugation.
RESULTS RESULTS
There was no difference between diets when comparing differences between bioLep and total leptin levels and their ratio in the 13 participants, three women and 10 men, aged 52-74 years with a mean BMI of 30 kg/m
CONCLUSIONS CONCLUSIONS
We found no leptin binding inhibition after the Paleolithic or diabetes diet, possibly due to its abolishment from cooking-related heat treatment of wheat gluten.
TRIAL REGISTRATION BACKGROUND
Registered on 14/02/2007 at ClinicalTrials.gov Identifier: NCT00435240.

Identifiants

pubmed: 39232748
doi: 10.1186/s12902-024-01715-0
pii: 10.1186/s12902-024-01715-0
doi:

Substances chimiques

Leptin 0

Banques de données

ClinicalTrials.gov
['NCT00435240']

Types de publication

Journal Article Randomized Controlled Trial Comparative Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

176

Informations de copyright

© 2024. The Author(s).

Références

Eaton SB, Konner M. Paleolithic nutrition. A consideration of its nature and current implications. N Engl J Med. 1985;312:283–9.
doi: 10.1056/NEJM198501313120505 pubmed: 2981409
Lindeberg S. Paleolithic diets as a model for prevention and treatment of Western disease. Am J Hum Biol. 2012;24:110–5.
doi: 10.1002/ajhb.22218 pubmed: 22262579
Carrera-Bastos P, Fontes-Villalba M, O’Keefe JH, Lindeberg S, Cordain L. The western diet and lifestyle and diseases of civilization. Res Rep Clin Cardiol. 2011;2:15–35.
Manheimer EW, van Zuuren EJ, Fedorowicz Z, Pijl H. Paleolithic nutrition for metabolic syndrome: systematic review and meta-analysis. Am J Clin Nutr. 2015;102:922–32.
doi: 10.3945/ajcn.115.113613 pubmed: 26269362 pmcid: 4588744
Ghaedi E, Mohammadi M, Mohammadi H, Ramezani-Jolfaie N, Malekzadeh J, Hosseinzadeh M, et al. Effects of a Paleolithic Diet on Cardiovascular Disease Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv Nutrition Bethesda Md. 2019;10:634–46.
doi: 10.1093/advances/nmz007
Sohouli MH, Fatahi S, Lari A, Lotfi M, Seifishahpar M, Găman M-A, et al. The effect of paleolithic diet on glucose metabolism and lipid profile among patients with metabolic disorders: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci. 2022;62:4551–62.
doi: 10.1080/10408398.2021.1876625
de Menezes EVA, de Sampaio HAC, Carioca AAF, Parente NA, Brito FO, Moreira TMM, et al. Influence of Paleolithic diet on anthropometric markers in chronic diseases: systematic review and meta-analysis. Nutr J. 2019;18:41.
doi: 10.1186/s12937-019-0457-z pubmed: 31337389 pmcid: 6647066
Jönsson T, Granfeldt Y, Ahrén B, Branell U-C, Pålsson G, Hansson A, et al. Beneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot study. Cardiovasc Diabetol. 2009;8:35.
doi: 10.1186/1475-2840-8-35 pubmed: 19604407 pmcid: 2724493
Jönsson T, Granfeldt Y, Lindeberg S, Hallberg A-C. Subjective satiety and other experiences of a Paleolithic diet compared to a diabetes diet in patients with type 2 diabetes. Nutr J. 2013;12:105.
doi: 10.1186/1475-2891-12-105 pubmed: 23890471 pmcid: 3727993
Fontes-Villalba M, Lindeberg S, Granfeldt Y, Knop FK, Memon AA, Carrera-Bastos P, et al. Palaeolithic diet decreases fasting plasma leptin concentrations more than a diabetes diet in patients with type 2 diabetes: a randomised cross-over trial. Cardiovasc Diabetol. 2016;15:80.
doi: 10.1186/s12933-016-0398-1 pubmed: 27216013 pmcid: 4877952
Mendoza-Herrera K, Florio AA, Moore M, Marrero A, Tamez M, Bhupathiraju SN, et al. The leptin system and diet: a mini review of the current evidence. Front Endocrinol. 2021;12: 749050.
doi: 10.3389/fendo.2021.749050
Jönsson T, Memon AA, Sundquist K, Sundquist J, Olsson S, Nalla A, et al. Digested wheat gluten inhibits binding between leptin and its receptor. BMC Biochem. 2015;16:3.
doi: 10.1186/s12858-015-0032-y pubmed: 25600821 pmcid: 4308898
Wabitsch M, Pridzun L, Ranke M, von Schnurbein J, Moss A, Brandt S, et al. Measurement of immunofunctional leptin to detect and monitor patients with functional leptin deficiency. Eur J Endocrinol. 2016;176:315–22.
doi: 10.1530/EJE-16-0821 pubmed: 28007844 pmcid: 5292973
Rydhög B, Granfeldt Y, Frassetto L, Fontes-Villalba M, Carrera-Bastos P, Jönsson T. Assessing compliance with Paleolithic diet by calculating Paleolithic Diet Fraction as the fraction of intake from Paleolithic food groups. Clin Nutrition Exp. 2019;25:29–35.
doi: 10.1016/j.yclnex.2019.03.002
Mann JI, Leeuw ID, Hermansen K, Karamanos B, Karlström B, Katsilambros N, et al. Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis. 2004;14:373–94.
doi: 10.1016/S0939-4753(04)80028-0 pubmed: 15853122
Rydhög B, Granfeldt Y, Sundquist K, Jönsson T. Paleolithic diet fraction in post hoc data analysis of a randomized cross-over study comparing Paleolithic diet with diabetes diet. Clin Nutrition Open Sci. 2021;38:73–80.
doi: 10.1016/j.nutos.2021.07.001
Chirdo FG, Rumbo M, Añón MC, Fossati CA. Presence of high levels of non-degraded gliadin in breast milk from healthy mothers. Scand J Gastroenterol. 1998;33:1186–92.
doi: 10.1080/00365529850172557 pubmed: 9867098
Miner-Williams WM, Stevens BR, Moughan PJ. Are intact peptides absorbed from the healthy gut in the adult human? - PubMed - NCBI. NRR. 2015;27:308–29.
doi: 10.1017/S0954422414000225
Rosano GL, Ceccarelli EA. Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol. 2014;5:172.
doi: 10.3389/fmicb.2014.00172 pubmed: 24860555 pmcid: 4029002
Biesiekierski JR. What is gluten? J Gastroen Hepatol. 2017;32:78–81.
doi: 10.1111/jgh.13703
FAOSTAT. https://www.fao.org/faostat/en/#data/FBS . Accessed 23 Jan 2023.
Greco M, Santo MD, Comandè A, Belsito EL, Andò S, Liguori A, et al. Leptin-Activity Modulators and Their Potential Pharmaceutical Applications. Biomol. 2021;11:1045.
Husby S, Jensenius JC, Svehag S-E. Passage of Undegraded Dietary Antigen into the Blood of Healthy Adults. Scand J Immunol. 1985;22:83–92.
doi: 10.1111/j.1365-3083.1985.tb01862.x pubmed: 4023632

Auteurs

Maelán Fontes-Villalba (M)

Center for Primary Health Care Research. Department of Clinical Sciences. Malmö, Lund University, Malmö, Sweden. maelan.fontes_villalba@med.lu.se.
, Costa Teguise, Spain. maelan.fontes_villalba@med.lu.se.

Yvonne Granfeldt (Y)

Deparment of Process and Life Science Engineering, Lund University, Lund, Sweden.

Kristina Sundquist (K)

Center for Primary Health Care Research. Department of Clinical Sciences. Malmö, Lund University, Malmö, Sweden.
University Clinic Primary Care Skåne, Region Skåne, Malmö, Sweden.

Ashfaque A Memon (AA)

Center for Primary Health Care Research. Department of Clinical Sciences. Malmö, Lund University, Malmö, Sweden.

Anna Hedelius (A)

Center for Primary Health Care Research. Department of Clinical Sciences. Malmö, Lund University, Malmö, Sweden.

Pedro Carrera-Bastos (P)

Center for Primary Health Care Research. Department of Clinical Sciences. Malmö, Lund University, Malmö, Sweden.

Tommy Jönsson (T)

Center for Primary Health Care Research. Department of Clinical Sciences. Malmö, Lund University, Malmö, Sweden.
University Clinic Primary Care Skåne, Region Skåne, Malmö, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH